Analysis of sensory tricks in 45 patients with pantothenate kinase-associated neurodegeneration
Objective: To analyze and classify sensory tricks developed by patients with dystonia in the setting of pantothenate kinase-associated neurodegeneration (PKAN). Background: PKAN is a progressive…Cohort profile of the Japan Dystonia Consortium: Genetic diagnosis and characteristics of movement disorders in Japan
Objective: To reveal molecular epidemiology of hereditary dystonia through resequencing of the currently-known dystonia genes and identification of novel genetic defects. Background: The Japan Dystonia…Prevelance in the World
Objective: To analyze the static data in the incidence of Parkinson disease in the world. Background: Parkinson’s disease is considered a progressive multisystem disorder involving…A randomized, double-blind, placebo-controlled Phase II Efficacy and Safety Study of the PDE10A inhibitor PF-02545920 in Huntington Disease (AMARYLLIS)
Objective: To assess efficacy on motor function, safety and tolerability of the phosphodiesterase-10A inhibitor PF-02545920 in Huntington disease (HD). Conclusion: PF-02545920 was generally safe and…Neuroprotective role of cinnamaldehyde against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington’s disease
Objective: The present study examined the potential therapeutic effects of CA against 3-nitropropionic acid (3-NP)-induced oxidative stress in a rat model of HD and explored…Motor and Non-motor Features Predict Freezing of Gait in Parkinson’s Disease
Objective: To investigate and evaluate behavioral predictors of conversion to Freezing of Gait in Parkinson’s Disease (PD). Background: Freezing of Gait (FOG) has devastating consequences…Relationship of 10-Meter Walk Test to balance performance in Parkinson’s disease patients as a predictor of falls
Objective: This study aimed to clarify the relationship between the 10-Meter Walk Test (10-MWT) and balance performance in PD. Background: Patients with Parkinson's disease (PD)…Assessing the potential cost-effectiveness of ads-5102 (Amantadine HCl) for the treatment of dyskinesia in Parkinson’s disease patients
Objective: This economic evaluation projects the likely cost-effectiveness of ADS-5102 in comparison to the current standard of best supportive care. Background: In August, 2017, the…Exploring The Role of a Prescribing Pharmacist in the Management of Parkinson’s Disease
Objective: Aims/Objectives A review to explore the role of a pharmacist NMP within the neurology PD multidisciplinary team during a six month period between 1st…Home Care Programme for Patients with Parkinsonism
Objective: To review patients and caregivers’ feedback on the service for the period from mid Oct 2015 to June 2017 as part of quality improvement…
- « Previous Page
- 1
- …
- 169
- 170
- 171
- 172
- 173
- …
- 177
- Next Page »